Clinical trial
Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis
NCT01287195 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 7, 2011
- Completion date
- May 2, 2013
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ulcerative colitis